Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Company Overview

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $0.42 to $0.49
• 50-Day Range: $0.42 to $0.96
• 52-Week Range: $0.19 to $1.77
• Volume: 905,400 shs
• Average Volume: 2.91 million shs
• Market Capitalization: $23.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Cardio Diagnostics Stock Analysis - MarketRank™

Cardio Diagnostics scored higher than 45% of companies evaluated by MarketBeat, and ranked 550th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cardio Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cardio Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cardio Diagnostics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.90% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently increased by 43.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardio Diagnostics does not currently pay a dividend.

Dividend Growth

Cardio Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.90% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently increased by 43.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Cardio Diagnostics has a news sentiment score of 1.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

Search Interest

13 people have searched for CDIO on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.30% of the stock of Cardio Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.06% of the stock of Cardio Diagnostics is held by institutions.

CDIO Stock Analysis - Frequently Asked Questions

How have CDIO shares performed this year?

Cardio Diagnostics' stock was trading at $0.9170 at the beginning of 2025. Since then, CDIO shares have decreased by 50.7% and is now trading at $0.4523.
View the best growth stocks for 2025 here.

How were Cardio Diagnostics' earnings last quarter?

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.07. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.13 million. Cardio Diagnostics had a negative net margin of 22,732.03% and a negative trailing twelve-month return on equity of 258.85%.

Who are Cardio Diagnostics' major shareholders?

Top institutional investors of Cardio Diagnostics include Geode Capital Management LLC (0.90%), Millennium Management LLC (0.64%), Jane Street Group LLC (0.28%) and Two Sigma Securities LLC (0.13%). Insiders that own company stock include Robert Philibert and Meeshanthini Dogan.
View institutional ownership trends.

How do I buy shares of Cardio Diagnostics?

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX) and SoundHound AI (SOUN).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 3/09/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDIO
• CIK: 1870144
• Web: cardiodiagnosticsinc.com
• Phone: 302-281-2147
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +342.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,380,000.00
• Net Margins: -22,732.03%
• Pretax Margin: -22,732.03%
• Return on Equity: -258.85%
• Return on Assets: -191.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.50
• Quick Ratio: 8.50

Sales & Book Value

• Annual Sales: $35,688.00
• Price / Sales: 660.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 52,145,000
• Free Float: 40,517,000
• Market Cap: $23.59 million
• Optionable: Not Optionable
• Beta: 3.61